Dalhousie University, Division of Otolaryngology - Head and Neck Surgery, Halifax, NS, Canada.
J Otolaryngol Head Neck Surg. 2013 Mar 19;42(1):22. doi: 10.1186/1916-0216-42-22.
To assess the oncological and functional outcomes of T1b squamous cell carcinoma (SCC) of the glottic larynx treated with laser in comparison with radiation.
A Canadian multicenter cohort study.
Three tertiary referral centers for head and neck cancer- Dalhousie University in Halifax, Nova Scotia, Western University in London, Ontario and the University of Manitoba, Winnipeg.
Patients with T1b glottic SCC who underwent transoral laser resection or radiation as the primary modality of treatment.
Oncological outcomes were evaluated using local control, laryngeal preservation, disease free survival and disease specific survival. Voice outcomes were assessed using the Voice Handicap Index-10 (VHI-10).
63 patients met study criteria. 21 were treated with laser and 42 with radiation. Oncologic outcomes at 2 years for laser and radiation demonstrated local control of 95% and 85.9%; laryngeal preservation of 100% and 85.9%; disease free survival of 88.7% and 85.9% and overall survival of 94.1% and 94.8% respectively. VHI-10 data was available for 23/63 patients. During the last follow up visit VHI-10 ranged from 0 to 11 (median 6) in the laser group and 0 to 34 (median 7) in the radiation group.
T1b SCC of the glottis can be effectively treated with transoral laser microsurgery with oncological outcomes that are at least equivalent to radiation. For patients with VHI scores, voice quality was similar between the two groups. To our knowledge this is the first study directly comparing the oncologic and voice outcomes with laser and radiation for the treatment of glottic cancer involving the anterior commissure.
评估 T1b 声门型鳞状细胞癌(SCC)经激光治疗与放疗的肿瘤学和功能结局。
加拿大多中心队列研究。
三家头颈癌三级转诊中心——新斯科舍省哈利法克斯的达尔豪西大学、安大略省伦敦的西安大略大学和马尼托巴大学温尼伯分校。
采用经口激光切除术或放疗作为主要治疗方式的 T1b 声门型 SCC 患者。
采用局部控制、喉保留、无病生存率和疾病特异性生存率评估肿瘤学结局。采用嗓音障碍指数-10(VHI-10)评估嗓音结局。
63 例患者符合研究标准。21 例接受激光治疗,42 例接受放疗。激光和放疗组 2 年肿瘤学结局显示局部控制率分别为 95%和 85.9%;喉保留率分别为 100%和 85.9%;无病生存率分别为 88.7%和 85.9%;总生存率分别为 94.1%和 94.8%。63 例患者中有 23 例可获得 VHI-10 数据。在最后一次随访时,激光组 VHI-10 评分范围为 0-11(中位数为 6),放疗组 VHI-10 评分范围为 0-34(中位数为 7)。
T1b 声门型 SCC 可通过经口激光微创手术有效治疗,其肿瘤学结局至少与放疗相当。对于 VHI 评分患者,两组间的嗓音质量相似。据我们所知,这是第一项直接比较累及前联合的声门型癌症激光与放疗治疗的肿瘤学和嗓音结局的研究。